Number of NDA of innovative drugs submitted in China 2018-2021
In 2021, the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China received more than 65 New Drug Applications (NDA) for innovative drugs. Most NDA applications were concerning innovative chemical drugs or biopharmaceuticals, with only ten innovative Traditional Chinese Medicine (TCM) NDA applications submitted in 2021. A New Drug Application (NDA) is the mechanism through which pharmaceutical manufacturers propose that the regulatory body approve a new drug or biopharmaceutical for general use and sale.